Lung cancers with SMARCA4 deficiency are rare, typically showing aggressive behavior and poor prognosis. These tumors rarely harbor common targetable oncogenes like EGFR, ALK, or ROS1. This case report details a nonsmoking middle-aged woman with SMARCA4-deficient non-small cell lung cancer (NSCLC) and rare EGFR mutations who achieved significant tumor response with afatinib.

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise but their efficacy varies, highlighting the need for biomarkers. This study explores TRIM4's role in ovarian cancer's response to CDK4/6 inhibitors, revealing that TRIM4, an E3 ligase, influences sensitivity by modulating hnRNPDL and CDKN2C levels.

Timely follow-up colonoscopies can reduce the mortality rate from colorectal cancer, and patient navigators can play an important role in facilitating screening, according to researchers at the U of A Cancer Center.

Brian Brown, PhD, Director of the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai, has been elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE). He was honored for his seminal work in gene therapy and functional genomics, which has helped transform the fields and contributed to key advancements in medicine and biotechnology. Election to the AIMBE College of Fellows is one of the highest professional distinctions in the field. It recognizes the top two percent of experts in medical and biological engineering, and its members are celebrated for their exceptional work in the field. Members are honored for their outstanding contributions to "engineering and medicine research, practice, or education” and to "the pioneering of new and developing fields of technology." Dr. Brown’s election recognizes his groundbreaking work developing innovative technologies that have been broadly used across biomedical fields, including in cancer, immunology, and genetic disease research and therapeutic development.

SUGAR LAND, Texas ― The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services and MD Anderson’s unparalleled patient experience closer to those living in Southwest Houston and the surrounding areas.

As warehouses go, nuclei are more like libraries than bank vaults. Too many cellular components need access to the genome to lock it down like Fort Knox. Instead, large groupings of more than 1,000 individual protein molecules called nuclear pore complexes (NPCs) pepper the dividing membrane, serving as gateways for materials and messages entering and exiting the nucleus.

A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this disease, reducing the extent of vascular malformations and lesion-associated pain in animal models. The research, led by Dr. Sandra Castillo, Dr. Eulàlia Baslega and Dr. Mariona Graupera, from the SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, and the Josep Carreras Leukaemia Research Institute, respectively, suggests the repurposing of these drugs may offer a new hope for PHTS patients, especially at younger ages. The research has been published in Cancer Discovery, a journal of the American Association for Cancer Research.